These observations of clinical efficacy of selpercatinib in MTC patients with RET E632_L633del are supported by preclinical data from a functional assay on Ba/F3 cells transformed with RET (E632_L633del) or other relevant RET alterations. This evidence concerns the gene RET and medullary thyroid gland carcinoma.